Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
Roberto MinutoloPiergiorgio BolascoPaolo ChiodiniStefano SposiniMaurizio BorzumatiCataldo AbaterussoAlessandra A MeleDomenico SantoroValeria CanaleAlberto SantoboniOliviero FilibertiFulvio FioriniCarlo MuraPatrizio ImperialiSilvio BorrelliLuigi RussoLuca De NicolaDomenico RussoPublished in: Clinical drug investigation (2018)
In stable dialysis patients, switching from ESA originators to biosimilars requires 40% higher doses to maintain anemia control.